Akso Biotech Completes Tens of Millions RMB Pre-A Financing Led by Delian Capital to Advance Monodisperse Microsphere Production

Recently, Suzhou Acasome Biotechnology Co., Ltd. (“Acasome Biotech”), a company dedicated to the R&D of high-throughput microfluidics technology and the development of a monodisperse microsphere preparation platform, has completed a Pre-A financing round worth tens of millions of yuan. This round was solely led by Delian Capital, with existing investor STEPPE CAPITAL continuing to increase its follow-on investment. The raised funds will be primarily used for the development of its technology platform and related products, production line establishment, as well as commercial projects and market expansion.

Chen Jiake, Founder and Chairman of Arcaso BioStatement: We express our gratitude to both new and existing shareholders for their recognition and support. Few realize that microfluidics is not merely a superior product, but also a powerful tool. Acasso Bio will continue its R&D efforts to promote the integration and industrialization of high-throughput microfluidic technologies, set industry benchmarks, and enable the application of monodisperse microbeads in a broader range of fields.

The company will continue to upgrade its existing chip fabrication processes and complete equipment sets, advancing toward a larger-scale and more stable production system. Meanwhile, it will focus on two key areas—purification filler microspheres and medical aesthetic microspheres—by establishing comprehensive capabilities in microsphere scaffold design and conjugation modification technologies, with an emphasis on commercialization to deliver higher-quality products and services to customers and partners.

Li Qin, Delian Capital, the lead investor in this roundIt indicates that technological advancements have deepened human understanding of life sciences to the micro- and nanoscale. Microspheres are the most critical foundational materials in the fields of medicine and pharmaceuticals, finding extensive applications in drug purification, drug delivery, diagnostics, and medical aesthetics. However, a persistent challenge for the industry has been the manufacturing process of microspheres, where it is difficult to simultaneously achieve high particle size uniformity and high production capacity. Enhancing particle size uniformity can significantly improve performance across many application areas. We focus on the performance advantages brought by equipment and process innovations at the application level. Acasobio has successfully addressed the challenge of large-scale production of monodisperse microspheres through technological innovation.

After more than a year of refinement, mass production of microspheres made from various materials has been achieved. In product development, Acasso Bio is not merely imitating or substituting imported products; instead, it enhances the performance of domestically produced products through engineering innovation. We believe that Acasso Bio’s products will rapidly empower the industry and create value for customers.

Acaso Bio, founded in 2021, specializes in the research, development, and manufacturing of microsphere products leveraging high-throughput microfluidics technology. With the goal of “building a smart manufacturing chip factory for high-performance microspheres,” the company has innovatively developed the world’s first high-throughput microfluidic chip with thousands of channels, along with equipment for large-scale mass production. By integrating disciplines such as molecular biology, biochemistry, and polymeric nanomaterials, Acaso Bio has established multiple technology platforms, including chromatography resins, immunomagnetic beads, medical aesthetics microspheres, and drug-loaded microsphere formulations.

The products are widely used in life sciences, in vitro diagnostics (IVD), consumer healthcare, and biopharmaceuticals, providing customers with one-stop procurement services. Acasor Bio will continue to accelerate the R&D of microspheres with diverse types and materials, establishing a proprietary technology system that covers the entire chain of design, development, and production for both biological and pharmaceutical microspheres, built upon the “Lab-on-a-Chip Factory” infrastructure platform.